Litigation Summary and Analysis for Supernus Pharmaceuticals, Inc. v. Appco Pharma LLC | 1:25-cv-00807
Introduction
Supernus Pharmaceuticals, Inc. filed a patent infringement lawsuit against Appco Pharma LLC in the United States District Court for the District of Columbia, case number 1:25-cv-00807, challenging alleged infringement of patents covering Supernus’s proprietary formulations. This case exemplifies ongoing patent disputes within the pharmaceutical industry, emphasizing the protection of innovative drug formulations amidst generic competition.
Case Background
Supernus Pharmaceuticals, a manufacturer of CNS and neuropsychiatric therapeutics, holds patents related to specific extended-release formulations of central nervous system drugs. The Patents-in-suit encompass claims directed to delayed-release formulations designed to improve therapeutic efficacy and patient compliance, notably involving formulations for the treatment of ADHD and epilepsy.
Appco Pharma LLC, a generic pharmaceutical manufacturer, launched a product identical or similar to Supernus’s protected formulations, prompting Supernus to initiate litigation asserting patent infringement. The allegations primarily focus on Appco’s alleged replication of the patented delivery systems and formulations post patent expiry or during patent-term.
